Literature DB >> 11207051

Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

N Bijker1, J L Peterse, L Duchateau, E C Robanus-Maandag, C A Bosch, C Duval, S Pilotti, M J van de Vijver.   

Abstract

We have investigated primary ductal carcinomas in situ (DCIS) of the breast and their local recurrences after breast-conserving therapy (BCT) for histological characteristics and marker expression. Patients who were randomized in the EORTC trial 10853 (wide local excision versus excision plus radiotherapy) and who developed a local recurrence were identified. Histology was reviewed for 116 cases; oestrogen and progesterone receptor status, and HER2/ neu and p53 overexpression were assessed for 71 cases. Comparing the primary DCIS and the invasive or non-invasive recurrence, concordant histology was found in 62%, and identical marker expression in 63%. Although 11% of the recurrences developed at a distance from the primary DCIS, nearly all these showed the same histological and immunohistochemical profile. 5 patients developed well-differentiated DCIS or grade I invasive carcinoma after poorly differentiated DCIS. Although these recurrences occurred in the same quadrant as the primary DCIS, they may be considered as second primary tumours. Only 4 patients developed poorly differentiated DCIS or grade III invasive carcinoma after well differentiated DCIS. We conclude that in most cases the primary DCIS and its local recurrence are related histologically or by marker expression, suggesting that local recurrence usually reflects outgrowth of residual DCIS; progression of well differentiated DCIS towards poorly differentiated DCIS or grade III invasive carcinoma is a non-frequent event. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207051      PMCID: PMC2363778          DOI: 10.1054/bjoc.2000.1618

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  The classification of ductal carcinoma in situ and its association with biological markers.

Authors:  L G Bobrow; L C Happerfield; W M Gregory; R D Springall; R R Millis
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

3.  Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences.

Authors:  F M Waldman; S DeVries; K L Chew; D H Moore; K Kerlikowske; B M Ljung
Journal:  J Natl Cancer Inst       Date:  2000-02-16       Impact factor: 13.506

4.  Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.

Authors:  C B Leal; F C Schmitt; M J Bento; N C Maia; C S Lopes
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

5.  Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast.

Authors:  R A Lininger; H Fujii; Y G Man; E Gabrielson; F A Tavassoli
Journal:  Mod Pathol       Date:  1998-12       Impact factor: 7.842

6.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

7.  Incidence of and treatment for ductal carcinoma in situ of the breast.

Authors:  V L Ernster; J Barclay; K Kerlikowske; D Grady; C Henderson
Journal:  JAMA       Date:  1996-03-27       Impact factor: 56.272

8.  Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component.

Authors:  O T Lampejo; D M Barnes; P Smith; R R Millis
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

9.  Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.

Authors:  B Zafrani; A Leroyer; A Fourquet; M Laurent; D Trophilme; P Validire; X Sastre-Garau
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

Review 10.  Ductal carcinoma in situ: a proposal for a new classification.

Authors:  R Holland; J L Peterse; R R Millis; V Eusebi; D Faverly; M J van de Vijver; B Zafrani
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

View more
  23 in total

Review 1.  Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective.

Authors:  Nina Bijker; Geertjan van Tienhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2010

2.  Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation.

Authors:  Aruna Turaka; Gary M Freedman; Tianyu Li; Penny R Anderson; Ramona Swaby; Nicos Nicolaou; Lori Goldstein; Elin R Sigurdson; Richard J Bleicher
Journal:  J Surg Oncol       Date:  2009-07-01       Impact factor: 3.454

3.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

4.  Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.

Authors:  Charles Bechert; Jee-Yeon Kim; Trine Tramm; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-09-23       Impact factor: 4.064

Review 5.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

6.  Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.

Authors:  Nils D Arvold; Rinaa S Punglia; Melissa E Hughes; Wei Jiang; Stephen B Edge; Sara H Javid; Christine Laronga; Joyce C Niland; Richard L Theriault; Jane C Weeks; Yu-Ning Wong; Sandra J Lee; Michael J Hassett
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

7.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

8.  Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Authors:  Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Breast Cancer Res Treat       Date:  2013-06-18       Impact factor: 4.872

9.  Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Authors:  Michael J Hassett; Wei Jiang; Laurel A Habel; Larissa Nekhlyudov; Ninah Achacoso; Luana Acton; Stuart J Schnitt; Deb Schrag; Rinaa S Punglia
Journal:  Breast Cancer Res Treat       Date:  2016-02-03       Impact factor: 4.872

Review 10.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.